Table 1.
CRISPR delivery vehicles and their common features. Relatively difficulty is a subjective measure of how difficult the delivery vehicle is to utilize overall on a four-point scale, where one point is ‘few reagents, facile kit provided’ and four points is ‘requires expert in field with significant experimental experience’.
Delivery vehicle | Composition | Most common cargo | Capacity | Advantages | Limitations | Ease of use | Text refs |
---|---|---|---|---|---|---|---|
Microinjection | Needle | DNA plasmid; mRNA (Cas9 + sgRNA); Protein (RNP) |
nM levels of Cas9 and sgRNA | Guaranteed delivery into cell of interest | Time-consuming; difficult; generally in vitro only | **** | Yang et al. (2013), Horii et al. (2014), Chuang et al. (2017), Nakagawa et al. (2015), Crispo et al. (2015), Raveux et al. (2017), Sato et al. (2015), Ma et al. (2014), Niu et al. (2014), Wu et al. (2013), Long et al. (2014), Ross (1995) |
Electroporation; nucleofection | Electric current | DNA plasmid; mRNA (Cas9 + sgRNA) |
nM levels of Cas9 and sgRNA | Delivery to cell population; well-known technique | Generally in vitro only; some cells not amenable | * | Hashimoto & Takemoto (2015), Chen et al. (2016), Qin et al. (2015), Matano et al. (2015), Paquet et al. (2016), Ousterout et al. (2015), Schumann et al. (2015), Wu et al. (2015), Ye et al. (2014), Choi et al. (2014), Wang et al. (2014), Zuckermann et al. (2015), Kim et al. (2014) |
Hydrodynamic delivery | High-pressure injection | DNA plasmid; Protein (RNP) | nM levels of Cas9 and sgRNA | Virus-free; low cost; ease | Non-specific; traumatic to tissues | ** | Yin et al. (2014), Guan et al. (2016), Xue et al. (2014), Lin et al. (2014), Zhen et al. (2015), Dong et al. (2015) |
Adeno-associated virus (AAV) | Non-enveloped, ssDNA | DNA plasmid | <5kb nucleic acid | Minimal immunogenicity | Low capacity | *** | Yang et al. (2013), Long et al. (2016), Carroll et al. (2016), Platt et al. (2014), Hung et al. (2016), Swiech et al. (2015), Chew et al. (2016), Truong et al. (2015), Ran et al. (2015), Nelson et al. (2016), Tabebordbar et al. (2016), Esvelt et al. (2013) |
Adenovirus | Non-enveloped, dsDNA | DNA plasmid | 8kb nucleic acid | High efficiency delivery | Inflammatory response; difficult scaled production | *** | Voets et al. (2017), Maddalo et al. (2014), Wang et al. (2015), Ding et al. (2014), Maggio et al. (2016), Li et al. (2015), Cheng et al. (2014) |
Lentivirus | Enveloped, RNA | DNA plasmid | ∼10kb, up to 18 kb nucleic acid | Persistent gene transfer | Prone to gene rearrangement; transgene silencing | *** | Shalem et al. (2014), Wang et al. (2014), Naldini et al. (1996), Kabadi et al. (2014), Heckl et al. (2014); Roehm et al. (2016), Koike-Yusa et al. (2014), Ma et al. (2015), Zhang et al. (2016), Platt et al. (2014) |
Lipid nanoparticles/ liposomes/lipoplexes | Natural or synthetic lipids or polymers | mRNA (Cas9 + sgRNA); Protein (RNP) | nM levels of Cas9 and sgRNA | Virus-free; simple manipulation; low cost | Endosomal degradation of cargo; specific cell tropism | ** | Yin et al. (2016), Wang et al. (2016), Zuris et al. (2015), Horii et al. (2013), Sakuma et al. (2014), Schwank et al. (2013), Liu et al. (2014), Liang et al. (2015), Kennedy et al. (2014), Miller et al. (2017), Ebina et al. (2013) |
Cell-penetrating peptides (CPPs) | Short amino acid sequences | Protein (RNP) | nM levels of Cas9 and sgRNA | Virus-free; can deliver intact RNP | Variable penetrating efficiency | ** | Ramakrishna et al. (2014), Axford et al. (2017) |
DNA nanoclew | DNA spheroid | Protein (RNP) | nM levels of Cas9 and sgRNA | Virus-free | Modifications for template DNA needed | **** | Sun et al. (2015), Sun et al. (2014) |
Gold nanoparticles (AuNPs) | Cationic arginine-coated AuNP | Protein (RNP) | nM levels of Cas9 and sgRNA | Inert; membrane-fusion-like delivery | Nonspecific inflammatory response | ** | Mout et al. (2017), Lee et al. (2017) |
iTOP | Hyperosmlality + transduction compound | Protein (RNP) | nM levels of Cas9 and sgRNA | Virus-free; high-efficiency | Non-specific; no in vivo use yet reported | *** | D'Astolfo et al. (2015) |
SLO | Bacterial pore-forming toxin | ∼100kDa proteins and complexes | Unknown for CRISPR | Reversible pore formation; no impact on cell viability | Not yet proven with CRISPR | *** | Sierig et al. (2003), Walev et al. (2001), Brito et al. (2008), Teng et al. (2017) |
MENDs | Poly-lysine core, lipid coating, CPP decoration | Nucleic acids | Unknown for CRISPR | Customizable; readily modified for precise delivery | Not yet proven with CRISPR | **** | Kogure et al. (2004), Nakamura et al. (2012) |
Lipid-coated mesoporous silica NPs | Mesoporous Si coated with lipid | Small molecules and short RNA sequences | Unknown for CRISPR | Inert; easy modification with targeting moieties | Not yet proven with CRISPR | *** | Liu et al. (2009), Du et al. (2014), Durfee et al. (2016), Gonzalez Porras et al. (2016), Mackowiak et al. (2013), Su et al. (2017), Wang et al. (2013) |
Inorganic NPs | NPs of various compositions (carbon, silica) | Large proteins, nucleic acids | Unknown for CRISPR | Inert; used for similar applications | Not yet proven with CRISPR | ** | Bates & Kostarelos (2013), Luo et al. (2014), Luo & Saltzman (2000) |